Fig. 5From: Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experienceAllodynia Symptom Checklist-12 (ASC-12) scores and Medical Outcomes Study (MOS) sleep scale scores at baseline (T0), and at the end of the third (T1) and of the sixth month (T2) of erenumab administrationBack to article page